Switch to:
Also traded in: Germany, Italy, Mexico, Spain, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.14
BAYRY's Cash to Debt is ranked lower than
91% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.46 vs. BAYRY: 0.14 )
Ranked among companies with meaningful Cash to Debt only.
BAYRY' s Cash to Debt Range Over the Past 10 Years
Min: 0.11  Med: 0.28 Max: No Debt
Current: 0.14
Equity to Asset 0.33
BAYRY's Equity to Asset is ranked lower than
86% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.62 vs. BAYRY: 0.33 )
Ranked among companies with meaningful Equity to Asset only.
BAYRY' s Equity to Asset Range Over the Past 10 Years
Min: 0.23  Med: 0.36 Max: 0.48
Current: 0.33
0.23
0.48
Interest Coverage 7.36
BAYRY's Interest Coverage is ranked lower than
70% of the 458 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.68 vs. BAYRY: 7.36 )
Ranked among companies with meaningful Interest Coverage only.
BAYRY' s Interest Coverage Range Over the Past 10 Years
Min: 2.86  Med: 5.71 Max: N/A
Current: 7.36
F-Score: 6
Z-Score: 2.10
M-Score: -2.60
WACC vs ROIC
9.29%
8.76%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 10.18
BAYRY's Operating margin (%) is ranked higher than
55% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.77 vs. BAYRY: 10.18 )
Ranked among companies with meaningful Operating margin (%) only.
BAYRY' s Operating margin (%) Range Over the Past 10 Years
Min: 7.78  Med: 10.11 Max: 11.36
Current: 10.18
7.78
11.36
Net-margin (%) 8.73
BAYRY's Net-margin (%) is ranked higher than
60% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.28 vs. BAYRY: 8.73 )
Ranked among companies with meaningful Net-margin (%) only.
BAYRY' s Net-margin (%) Range Over the Past 10 Years
Min: 3.71  Med: 6.41 Max: 14.55
Current: 8.73
3.71
14.55
ROE (%) 18.34
BAYRY's ROE (%) is ranked higher than
80% of the 739 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.27 vs. BAYRY: 18.34 )
Ranked among companies with meaningful ROE (%) only.
BAYRY' s ROE (%) Range Over the Past 10 Years
Min: 6.9  Med: 13.68 Max: 31.94
Current: 18.34
6.9
31.94
ROA (%) 5.48
BAYRY's ROA (%) is ranked higher than
59% of the 763 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.85 vs. BAYRY: 5.48 )
Ranked among companies with meaningful ROA (%) only.
BAYRY' s ROA (%) Range Over the Past 10 Years
Min: 2.54  Med: 4.68 Max: 8.78
Current: 5.48
2.54
8.78
ROC (Joel Greenblatt) (%) 30.19
BAYRY's ROC (Joel Greenblatt) (%) is ranked higher than
71% of the 755 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.64 vs. BAYRY: 30.19 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BAYRY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 17.91  Med: 25.65 Max: 33.37
Current: 30.19
17.91
33.37
Revenue Growth (3Y)(%) 5.20
BAYRY's Revenue Growth (3Y)(%) is ranked lower than
53% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.10 vs. BAYRY: 5.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BAYRY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.6  Med: 2.60 Max: 11.1
Current: 5.2
-10.6
11.1
EBITDA Growth (3Y)(%) 14.90
BAYRY's EBITDA Growth (3Y)(%) is ranked higher than
63% of the 543 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.90 vs. BAYRY: 14.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BAYRY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -9.9  Med: 3.20 Max: 15.4
Current: 14.9
-9.9
15.4
EPS Growth (3Y)(%) 18.80
BAYRY's EPS Growth (3Y)(%) is ranked higher than
68% of the 496 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.40 vs. BAYRY: 18.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BAYRY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -19.1  Med: 8.90 Max: 39.3
Current: 18.8
-19.1
39.3
» BAYRY's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-29)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

BAYRY Guru Trades in Q2 2015

Ken Fisher 4,610,296 sh (+83.74%)
» More
Q3 2015

BAYRY Guru Trades in Q3 2015

Ken Fisher 4,712,759 sh (+2.22%)
» More
Q4 2015

BAYRY Guru Trades in Q4 2015

Ken Fisher 4,709,574 sh (-0.07%)
» More
Q1 2016

BAYRY Guru Trades in Q1 2016

Ken Fisher 4,833,445 sh (+2.63%)
» More
» Details

Insider Trades

Latest Guru Trades with BAYRY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Bayer AG

Ken Fisher Cuts His Stake in Royal Bank, Buys Roche Holding Largest trades in second quarter include also Infosys and Alibaba
Ken Fisher (Trades, Portfolio) is the chief executive officer and chief investment officer of Fisher Investments, which offers an array of educational resources to its 27,000-plus private clients —including quarterly reports, in-person seminars and regular phone communication. Fisher Investments extends these educational resources to the public through a series of investing guides, online videos and daily commentary at MarketMinder.com. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 20.66
BAYRY's P/E(ttm) is ranked higher than
60% of the 540 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.10 vs. BAYRY: 20.66 )
Ranked among companies with meaningful P/E(ttm) only.
BAYRY' s P/E(ttm) Range Over the Past 10 Years
Min: 8.72  Med: 22.20 Max: 36.88
Current: 20.66
8.72
36.88
Forward P/E 13.62
BAYRY's Forward P/E is ranked higher than
58% of the 69 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.85 vs. BAYRY: 13.62 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 20.85
BAYRY's PE(NRI) is ranked higher than
60% of the 536 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.01 vs. BAYRY: 20.85 )
Ranked among companies with meaningful PE(NRI) only.
BAYRY' s PE(NRI) Range Over the Past 10 Years
Min: 14.08  Med: 23.35 Max: 37.39
Current: 20.85
14.08
37.39
Price/Owner Earnings (ttm) 19.19
BAYRY's Price/Owner Earnings (ttm) is ranked higher than
72% of the 261 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.99 vs. BAYRY: 19.19 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
BAYRY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 7.44  Med: 16.40 Max: 96.52
Current: 19.19
7.44
96.52
P/B 3.47
BAYRY's P/B is ranked lower than
62% of the 727 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.94 vs. BAYRY: 3.47 )
Ranked among companies with meaningful P/B only.
BAYRY' s P/B Range Over the Past 10 Years
Min: 1.54  Med: 2.47 Max: 5.56
Current: 3.47
1.54
5.56
P/S 1.81
BAYRY's P/S is ranked higher than
61% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.78 vs. BAYRY: 1.81 )
Ranked among companies with meaningful P/S only.
BAYRY' s P/S Range Over the Past 10 Years
Min: 0.87  Med: 1.33 Max: 2.8
Current: 1.81
0.87
2.8
PFCF 19.23
BAYRY's PFCF is ranked higher than
61% of the 194 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 29.93 vs. BAYRY: 19.23 )
Ranked among companies with meaningful PFCF only.
BAYRY' s PFCF Range Over the Past 10 Years
Min: 7.27  Med: 17.68 Max: 183.56
Current: 19.23
7.27
183.56
POCF 12.17
BAYRY's POCF is ranked higher than
67% of the 253 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.08 vs. BAYRY: 12.17 )
Ranked among companies with meaningful POCF only.
BAYRY' s POCF Range Over the Past 10 Years
Min: 5.51  Med: 9.66 Max: 19.38
Current: 12.17
5.51
19.38
EV-to-EBIT 17.22
BAYRY's EV-to-EBIT is ranked higher than
53% of the 526 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.82 vs. BAYRY: 17.22 )
Ranked among companies with meaningful EV-to-EBIT only.
BAYRY' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.2  Med: 17.30 Max: 27.9
Current: 17.22
7.2
27.9
EV-to-EBITDA 10.95
BAYRY's EV-to-EBITDA is ranked higher than
68% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.62 vs. BAYRY: 10.95 )
Ranked among companies with meaningful EV-to-EBITDA only.
BAYRY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.4  Med: 9.90 Max: 17.1
Current: 10.95
4.4
17.1
PEG 2.97
BAYRY's PEG is ranked lower than
62% of the 281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.88 vs. BAYRY: 2.97 )
Ranked among companies with meaningful PEG only.
BAYRY' s PEG Range Over the Past 10 Years
Min: 0.6  Med: 3.44 Max: 939.5
Current: 2.97
0.6
939.5
Shiller P/E 29.44
BAYRY's Shiller P/E is ranked higher than
67% of the 140 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 45.65 vs. BAYRY: 29.44 )
Ranked among companies with meaningful Shiller P/E only.
BAYRY' s Shiller P/E Range Over the Past 10 Years
Min: 20.31  Med: 33.02 Max: 44.71
Current: 29.44
20.31
44.71
Current Ratio 1.40
BAYRY's Current Ratio is ranked lower than
75% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.41 vs. BAYRY: 1.40 )
Ranked among companies with meaningful Current Ratio only.
BAYRY' s Current Ratio Range Over the Past 10 Years
Min: 1.24  Med: 1.57 Max: 2.21
Current: 1.4
1.24
2.21
Quick Ratio 0.90
BAYRY's Quick Ratio is ranked lower than
79% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. BAYRY: 0.90 )
Ranked among companies with meaningful Quick Ratio only.
BAYRY' s Quick Ratio Range Over the Past 10 Years
Min: 0.76  Med: 1.00 Max: 1.48
Current: 0.9
0.76
1.48
Days Inventory 148.36
BAYRY's Days Inventory is ranked lower than
67% of the 659 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 113.44 vs. BAYRY: 148.36 )
Ranked among companies with meaningful Days Inventory only.
BAYRY' s Days Inventory Range Over the Past 10 Years
Min: 126.65  Med: 138.65 Max: 154.01
Current: 148.36
126.65
154.01
Days Sales Outstanding 77.86
BAYRY's Days Sales Outstanding is ranked lower than
53% of the 610 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.18 vs. BAYRY: 77.86 )
Ranked among companies with meaningful Days Sales Outstanding only.
BAYRY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 65.71  Med: 69.96 Max: 80.32
Current: 77.86
65.71
80.32
Days Payable 102.12
BAYRY's Days Payable is ranked higher than
67% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.90 vs. BAYRY: 102.12 )
Ranked among companies with meaningful Days Payable only.
BAYRY' s Days Payable Range Over the Past 10 Years
Min: 54.65  Med: 75.75 Max: 102.56
Current: 102.12
54.65
102.56

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.46
BAYRY's Dividend Yield is ranked higher than
67% of the 563 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.56 vs. BAYRY: 2.46 )
Ranked among companies with meaningful Dividend Yield only.
BAYRY' s Dividend Yield Range Over the Past 10 Years
Min: 1.44  Med: 2.28 Max: 3.93
Current: 2.46
1.44
3.93
Dividend Payout 0.46
BAYRY's Dividend Payout is ranked lower than
63% of the 365 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. BAYRY: 0.46 )
Ranked among companies with meaningful Dividend Payout only.
BAYRY' s Dividend Payout Range Over the Past 10 Years
Min: 0.29  Med: 0.50 Max: 0.89
Current: 0.46
0.29
0.89
Dividend Growth (3y) 10.90
BAYRY's Dividend Growth (3y) is ranked higher than
59% of the 280 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. BAYRY: 10.90 )
Ranked among companies with meaningful Dividend Growth (3y) only.
BAYRY' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 3.60 Max: 34.9
Current: 10.9
0
34.9
Forward Dividend Yield 2.38
BAYRY's Forward Dividend Yield is ranked higher than
69% of the 527 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. BAYRY: 2.38 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 4.07
BAYRY's Yield on cost (5-Year) is ranked higher than
75% of the 715 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.32 vs. BAYRY: 4.07 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
BAYRY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.38  Med: 3.77 Max: 6.5
Current: 4.07
2.38
6.5

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.59
BAYRY's Price/Projected FCF is ranked higher than
66% of the 298 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.83 vs. BAYRY: 1.59 )
Ranked among companies with meaningful Price/Projected FCF only.
BAYRY' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.8  Med: 1.28 Max: 2.12
Current: 1.59
0.8
2.12
Price/DCF (Earnings Based) 1.46
BAYRY's Price/DCF (Earnings Based) is ranked lower than
58% of the 74 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.39 vs. BAYRY: 1.46 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.36
BAYRY's Price/Median PS Value is ranked lower than
66% of the 624 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.18 vs. BAYRY: 1.36 )
Ranked among companies with meaningful Price/Median PS Value only.
BAYRY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.39  Med: 0.92 Max: 1.69
Current: 1.36
0.39
1.69
Price/Peter Lynch Fair Value 1.67
BAYRY's Price/Peter Lynch Fair Value is ranked lower than
58% of the 174 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.59 vs. BAYRY: 1.67 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
BAYRY' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.75  Med: 1.91 Max: 5.74
Current: 1.67
0.75
5.74
Earnings Yield (Greenblatt) (%) 5.83
BAYRY's Earnings Yield (Greenblatt) (%) is ranked higher than
67% of the 738 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. BAYRY: 5.83 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BAYRY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.6  Med: 5.80 Max: 13.9
Current: 5.83
3.6
13.9
Forward Rate of Return (Yacktman) (%) 16.25
BAYRY's Forward Rate of Return (Yacktman) (%) is ranked higher than
66% of the 315 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.27 vs. BAYRY: 16.25 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BAYRY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -11.4  Med: 10.10 Max: 31.7
Current: 16.25
-11.4
31.7

More Statistics

Revenue(Mil) $52317
EPS $ 5.53
Beta1.19
Short Percentage of Float0.01%
52-Week Range $102.64 - 153.78
Shares Outstanding(Mil)826.95

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 51,090 53,546 55,351
EPS($) 7.95 8.23 9.23
EPS without NRI($) 7.95 8.23 9.23

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:JNJ, NYSE:PFE, XSWX:NOVN, NYSE:MRK, NYSE:BMY, XPAR:SAN » details
Traded in other countries:BAYA.Germany, BAY.Italy, BAYN N.Mexico, BAY.Spain, BAYN.Switzerland,
Bayer AG is an international research-based company active in life sciences, polymers, and chemicals. Bayer's operating units include health-care products, material sciences, and crop sciences. Bayer's over-the-counter health-care product division is the third- largest in the world. HealthCare subgroup is divided into two reporting segments: Pharmaceuticals and Consumer Health. The Pharmaceuticals segment focuses on prescription products, especially for women's healthcare and cardiology and also on specialty therapeutics in the fields of oncology, hematology and ophthalmology. Its Consumer Health segment includes the Consumer Care, Medical Care and Animal Health divisions. It mainly focus on non-prescription medicines, dietary supplements and dermatology products. Crop Science has businesses in seeds, crop protection and non-agricultural pest control. Crop science businesss has two operating segments: Crop Protection / Seeds and Environmental Science. Crop Protection / Seeds markets a portfolio of high-value seeds and traits along with chemical and biological pest management solutions, at the same time providing extensive customer service to the agriculture industry. Environmental Science focuses on non-agricultural applications, with a broad portfolio of pest control products and services for areas ranging from the home and garden sector to forestry. The Material Science unit develops, manufactures and markets high-tech polymer materials including polyurethane raw materials, polycarbonates, coating and adhesive raw materials and functional films. This subgroup also manufactures and markets selected inorganic basic chemicals. Material Science is organized into the Polyurethanes, Polycarbonates, and Coatings, Adhesives, Specialties business units, and the Industrial Operations area.
» More Articles for BAYRY

Headlines

Articles On GuruFocus.com
Ken Fisher Cuts His Stake in Royal Bank, Buys Roche Holding Oct 12 2015 
Ken Fisher's most weighted buys in Q2 2015 Jul 28 2015 
UnitedHealth Group Reports Strong Second Quarter Earnings Results Jul 21 2015 
Bayer AG Wins Approval On Existing Antibiotic For Plague Treatment May 12 2015 
Bayer Enters Into Collaboration With Isis For Enhancing Its Drug Portfolio May 07 2015 
DuPont Eyeing Acquisition To Leverage Its Market Spread Apr 24 2015 
Bayer Goes Into Disinvestment Mode Due To Falling Profit Numbers Feb 27 2015 
Zoetis Will Benefit from Industry Trends Oct 07 2014 
Baxter Will Remain Diversified and With Competitive Advantages Sep 02 2014 
Ken Fisher's Top Increaes of the Second Quarter Jul 28 2014 

More From Other Websites
“Innovation is our future” Apr 29 2016
Annual Stockholders’ Meeting 2016: -- Address by Dr. Marijn Dekkers -- Chairman of the Board of... Apr 29 2016
Bayer (BAYRY) Q1 Earnings Beat Estimates, Retains View Apr 27 2016
Bayer AG downgraded by Credit Suisse Apr 27 2016
Recent Drug Launches Buoy Bayer's Growth Apr 27 2016
What's in the Cards for ImmunoGen (IMGN) in Q3 Earnings? Apr 26 2016
Bayer Beats Earnings Estimates, Gets Boost From Pharma Sales Apr 26 2016
[$$] Bayer Posts 13% Jump in Net Profit Apr 26 2016
Interim report for the first quarter of 2016: Bayer off to a successful start in 2016 Apr 26 2016
Bayer Profit Beats Estimates as Newest Drugs Buoy Demand Apr 26 2016
Ironwood to decide soon on a target disease for its next potential blockbuster Apr 25 2016
Not intended for U.S. and UK Media -- Patent Term for Rivaroxaban Extended in US Apr 25 2016
Prestigious award from the Bayer Science & Education Foundation: -- 2016 Otto Bayer Award goes to... Apr 25 2016
Bayer showcases innovative approaches to drive sustainability in banana production Apr 21 2016
Bayer deposits 10 million Covestro shares in Bayer Pension Trust e. V. Apr 21 2016
Bayer and Hamburg University agree research collaboration: -- New digital solutions for sustainable... Apr 19 2016
New Data Reaffirm Positive Benefit-Risk Balance of Bayer’s Xarelto® in Patients with Atrial... Apr 18 2016
Investing in the future of agriculture: -- Bayer and Trendlines establish Ag Innovation Fund --... Apr 18 2016
Bayer Barks, But Will It Bite? Apr 15 2016
Latest innovation out of RTP? New Bayer wheat product Apr 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK